Pemetrexed

FDA Approved: * May 25, 2022
Pharm Company: * APP PHARMS
Category: Cancer

Pemetrexed, sold under the brand name Alimta among others, is a chemotherapy medication for the treatment of pleural mesothelioma and non-small cell lung cancer (NSCLC). Contents 1 Medical use 1.1 Carboplatin 1.2 Supplementation 2 Side effects 3 Mechanism of action 4 History 5 Society and culture 5.1 Trade names 5.2 Cost 6 Research 7 References 8 External links Medical use In February 2004, the U.S. Food and Drug Administration (FDA) approved pemetrexed for treatment of malignant... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Pemetrexed 100 mg/10ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 0338-0720
Labeler:
Baxter Healthcare Corporation
Pemetrexed 500 mg/50ml Intraventricular Injection, Powder, Lyophilized, for Solution
NDC: 0338-0722
Labeler:
Baxter Healthcare Corporation
Pemetrexed 100 mg/4ml Intravenous Injection, Solution, Concentrate
NDC: 0409-1045
Labeler:
Hospira, Inc.
Pemetrexed 25 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 0409-1060
Labeler:
Hospira, Inc.
Pemetrexed 25 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 0409-1061
Labeler:
Hospira, Inc.
Pemetrexed 25 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 0409-1062
Labeler:
Hospira, Inc.
Pemetrexed 500 mg/20ml Intravenous Injection, Solution, Concentrate
NDC: 0409-2188
Labeler:
Hospira, Inc.
Pemetrexed 1 g/40ml Intravenous Injection, Solution, Concentrate
NDC: 0409-3532
Labeler:
Hospira, Inc.
Pemetrexed 25 mg/ml Intravenous Solution, Concentrate
NDC: 0480-4514
Labeler:
Teva Pharmaceuticals, Inc.
Pemetrexed 25 mg/ml Intravenous Solution, Concentrate
NDC: 0480-4515
Labeler:
Teva Pharmaceuticals, Inc.

Related Brands

Drugs with the same active ingredients